World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
45217
World Ranking
10680
National Ranking
5491

Marc S. Ernstoff publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Marc S. Ernstoff sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 477 publications — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Marc S. Ernstoff D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Marc S. Ernstoff sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 93 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Marc S. Ernstoff is affiliated with the Roswell Park Cancer Institute in the United States. Their work primarily spans the fields of Medicine and Biochemistry, Genetics, and Molecular Biology, with a strong focus on Oncology, Molecular Biology, Immunology, Genetics, and Pulmonary and Respiratory Medicine.

The scientific contributions of Marc S. Ernstoff emphasize cancer-related immunotherapy and molecular research. Their main areas of study include:

  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • CAR-T Cell Therapy Research
  • Cutaneous Melanoma Detection and Management
  • Cancer Genomics and Diagnostics
  • Melanoma and MAPK Pathways
  • Brain Metastases and Treatment

Marc S. Ernstoff has published frequently in the following venues:

  • Journal for ImmunoTherapy of Cancer
  • Journal of Clinical Oncology
  • Regular and Young Investigator Award Abstracts
  • Annals of Oncology
  • Journal of Translational Medicine

Notable recent papers include:

  • "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events," 2021, Journal for ImmunoTherapy of Cancer
  • "NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020," 2020, Journal of the National Comprehensive Cancer Network
  • "COVID-19 and Cancer: a Comprehensive Review," 2020, Current Oncology Reports
  • "Systemic Therapy for Melanoma: ASCO Guideline," 2020, Journal of Clinical Oncology
  • "Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy," 2020, Annals of Oncology

Collaborations are a significant component of their research, frequently working with the following co-authors:

  • Igor Puzanov
  • Pauline Funchain
  • Irene Orlow
  • Eva Hernando
  • Nancy E. Thomas

Best Publications

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins

  • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

    Michael A. Postow;Jason Chesney;Anna C. Pavlick;Caroline Robert

  • Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

    John M. Kirkwood;Myla Hunt Strawderman;Marc S. Ernstoff;Thomas J. Smith

  • Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

    I. Puzanov;A. Diab;K. Abdallah;C. O. Bingham

  • High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

    John M. Kirkwood;Joseph G. Ibrahim;Jeffrey A. Sosman;Vernon K. Sondak

  • Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

    Hussein A. Tawbi;Peter A. Forsyth;Alain Algazi;Omid Hamid

  • Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial

    Kim Margolin;Marc S Ernstoff;Omid Hamid;Donald Lawrence

  • High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190

    John M. Kirkwood;Joseph G. Ibrahim;Vernon K. Sondak;Jon Richards

  • Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

    F Stephen Hodi;Jason Chesney;Anna C Pavlick;Caroline Robert

  • Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

    David F. McDermott;Meredith M. Regan;Joseph I. Clark;Lawrence E. Flaherty

  • Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

    Paul B. Chapman;Lawrence H. Einhorn;Michael L. Meyers;Scott Saxman

  • Arginase I–Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes

    Paulo C. Rodriguez;Marc S. Ernstoff;Claudia Hernandez;Michael Atkins

  • Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

    F. Stephen Hodi;Christopher L. Corless;Anita Giobbie-Hurder;Jonathan A. Fletcher

  • A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma

    John M. Kirkwood;Judith Manola;Joseph Ibrahim;Vernon Sondak

  • Management of Immunotherapy-Related Toxicities, Version 1.2019.

    John A. Thompson;Bryan J. Schneider;Julie Brahmer;Stephanie Andrews

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.

    Bryan J Schneider;Jarushka Naidoo;Bianca D Santomasso;Christina Lacchetti

  • Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events

    Julie R. Brahmer;Hamzah Abu-Sbeih;Paolo Antonio Ascierto;Jill Brufsky

  • VISTA Is an Immune Checkpoint Molecule for Human T Cells

    Janet Lines;Eirini Pantazi;Justin Mak;Lorenzo F Sempere

  • Homozygous deletions within human chromosome band 9p21 in melanoma.

    J W Fountain;M Karayiorgou;M S Ernstoff;J M Kirkwood

  • Interferons in the treatment of human cancer.

    J M Kirkwood;M S Ernstoff

Frequent Co-Authors

John M. Kirkwood
John M. Kirkwood University of Pittsburgh
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Igor Puzanov
Igor Puzanov Roswell Park Cancer Institute
Michael B. Atkins
Michael B. Atkins Georgetown University
Kim Margolin
Kim Margolin City Of Hope National Medical Center
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Paul K. Wallace
Paul K. Wallace Roswell Park Cancer Institute
F. Stephen Hodi
F. Stephen Hodi Harvard University
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
James H. Finke
James H. Finke Cleveland Clinic Lerner College of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Medicine isn’t the only pathway to a fulfilling healthcare career in the USA. A range of online degrees can expand your options, offering flexible routes into fast-growing professions. For instance, pursuing a nutritionist online degree is ideal for those interested in promoting public health and wellness through diet and nutritional science.

Interested in healthcare leadership? Enrolling in online mha programs prepares graduates for management roles in hospitals, clinics, or health agencies. For working nurses who want career advancement without on-campus commitments, rn to bsn programs without clinicals save time while building essential skills.

If you aspire to the highest clinical or academic nursing roles, the shortest online dnp program options offer advanced doctoral training in a streamlined format.

Each online pathway has unique admissions and licensure requirements, so it’s important to research them carefully before choosing your direction in healthcare.

Best Scientists Citing Marc S. Ernstoff

Trending Scientists

Recently Published Articles